Pharmacogenetics Newsletter Archives
Released Issues
2010; Volume 2
Issue 7: Question: Why should patients of Asian descent receive human leukocyte antigen (HLA)-B genetic testing before being prescribed carbamazepine (Carbatrol; Equetro; Tegretol)?
Issue 3: Question: What are the common genetic polymorphisms to cytochrome P450 (CYP) 2C19 that could impact drug metabolism?
2009; Volume 1
Issue 12: Question: What are some common genetic risk factors that put women at risk for developing venous thromboembolism (DVT and/or pulmonary embolism) when taking oral contraceptives (birth control pills)?
Issue 11: Question: What are some common lab tests or techniques used for determining single nucleotide genetic polymorphisms (SNPs) that can facilitate patient specific drug therapy?
Issue 10: Question: How do you interpret a single nucleotide polymorphism (SNPs) when reported in the medical literature? (ex. What does CYP2C19*3 mean and does it relate to its SNP, W212X (G636A)?)
Issue 9: Question: What are good online pharmacogenetic resources that clinicians should be aware of?
Issue 8: Question: How do known genetic polymorphisms to VKORC1 influence the safety and efficacy of warfarin (Coumadin®, Jantoven®)?
Issue 7: Question: What influences do genetic polymorphisms to cytochrome P-450 (CYP) 2C19 have on cardiovascular disease (CVD) outcomes in patients taking clopidogrel (Plavix®)?
Issue 6: Question: What is a single nucleotide polymorphism (SNP) and how does it impact drug therapy?
Issue 5: Question: How do oral contraceptives (birth control pills) increase the risk of clots or venous thromboembolisms (DVTs and pulmonary embolisms) in patients with the genetic polymorphism, Factor V Leiden?
Issue 4: Question: How do genetic polymorphisms to UGT1A1*28 increase the risk for life-threatening neutropenia when receiving irinotecan (Camptosar®)?
Issue 3: Question: How does a patient's genetics predispose them to abacavir (Ziagen®) induced hypersensitivity reaction that prevents future use of the drug for the treatment of HIV infection?
Issue 2: Question: How is warfarin (Coumadin®, Jantoven®) use in clinical practice influenced by known genetic polymorphisms to CYP450 2C9 and when is testing needed, if at all?
Issue 1: Question: What is pharmacogenetics and why should healthcare providers seek to understand it?
Upcoming Issues
2010; Volume 2
Issue 11: Question: What common genetic polymorphisms to vitamin K 2,3-epoxide reductase complex C1 (VKORC1) are known to influence the pharmacologic properties of warfarin (Coumadin, Jantoven)?
Share
